Grifols (GRFS) Liabilities and Shareholders Equity (2009 - 2025)

Grifols (GRFS) posted Liabilities and Shareholders Equity of $22.9 billion for Q4 2025, little changed quarter-over-quarter from $22.9 billion in Q4 2024, and little changed year-on-year from $22.9 billion in Q4 2024.

Grifols (GRFS) Liabilities and Shareholders Equity (2009 - 2025) Analysis & Trends

Grifols (GRFS) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $22.9 billion the latest figure, recorded in Q4 2025.

  • Liabilities and Shareholders Equity for Q4 2025 came in at $22.9 billion, changed 0.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $90.1 billion (up 1.06% YoY), and the FY2025 annual result was $22.9 billion, up 28227.93% from the prior year.
  • Liabilities and Shareholders Equity was $22.9 billion for Q4 2025 at Grifols, roughly flat from $22.9 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $22.9 billion in Q4 2025 and troughed at $21.7 billion in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $22.4 billion, with a median of $22.6 billion recorded in 2023.
  • Year-over-year, Liabilities and Shareholders Equity gained 20.82% in 2021 and declined 1.56% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $22.0 billion in 2021, then slipped by 1.56% to $21.7 billion in 2022, then advanced by 4.28% to $22.6 billion in 2023, then increased by 1.27% to $22.9 billion in 2024, then increased by 0.32% to $22.9 billion in 2025.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $22.9 billion in Q4 2025, $22.9 billion in Q4 2024, and $22.6 billion in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 116.58 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 200.89 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 136.46 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 114.02 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 128.69 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 92.50 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 56.28 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 208.00 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Grifols - - - 22.95 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 22.95 Bn
Dec 31, 2024 22.87 Bn
Dec 31, 2023 22.59 Bn
Dec 31, 2022 21.66 Bn
Dec 31, 2021 22.00 Bn
Dec 31, 2020 18.21 Bn
Dec 31, 2019 17.20 Bn
Dec 31, 2018 14.24 Bn
Dec 31, 2017 12.86 Bn
Dec 31, 2016 10.94 Bn
Dec 31, 2015 10.52 Bn
Dec 31, 2014 10.56 Bn
Dec 31, 2013 7.95 Bn
Sep 30, 2013 7.57 Bn
Jun 30, 2013 7.63 Bn
Mar 31, 2013 7.64 Bn
Dec 31, 2012 7.30 Bn
Sep 30, 2012 7.30 Bn
Jun 30, 2012 7.60 Bn
Mar 31, 2012 7.27 Bn